Pull to refresh
Logo
What Changed
Following Why Sign Up
FDA approves first DNA-based immunotherapy for recurrent airway papillomas

FDA approves first DNA-based immunotherapy for recurrent airway papillomas

New Capabilities

Voceryq kept 7 of 26 adults surgery-free for 12 months, and Inovio must now confirm the benefit in a study running to 2032

October 30th, 2026: FDA grants accelerated approval to Voceryq

Overview

Updated 7 days ago

Adults with recurrent respiratory papillomatosis (RRP) have had one treatment: surgery to shave HPV-grown warts off the vocal cords and airway, often several times a year. On October 30, 2026, the Food and Drug Administration granted accelerated approval to Voceryq, an injected DNA-based immunotherapy meant to reduce how often those operations are needed.

In a 32-patient trial, 7 of the 26 evaluable adults needed no surgery in the 12 months after treatment. That 27% response rate is the basis for approval, and Inovio must confirm it in a study running to 2032. The FDA also required the company to reanalyze usability testing of the Cellectra 5PSP device that delivers the DNA and to verify its protection against sharps injuries.

Why it matters

RRP patients face repeated airway surgeries; Voceryq is the first approved therapy aimed at the HPV causing them, not just the growths.

Questions about this story

Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.

No questions yet — be the first to ask.

Key Indicators

7
Patients with no surgery at one year
Out of 26 patients who had at least two papilloma-removal procedures in the prior year.
2
Device testing commitments
Postmarketing studies the FDA required for the Cellectra 5PSP delivery device.

Voices

Curated perspectives — historical figures and your fellow readers.

Sign up to generate historical perspectives on this story.

Log in Sign Up

People Involved

JS
Jacqueline Shea
President and Chief Executive Officer, INOVIO
Leading INOVIO as its first approved product reaches the market and device testing commitments loom

Organizations Involved

INOVIO Pharmaceuticals
INOVIO Pharmaceuticals
Biotechnology company
Launching its first approved product while completing FDA-ordered device testing

A Pennsylvania biotech whose DNA medicines are delivered with its proprietary electroporation device.
U.S. Food and Drug Administration
U.S. Food and Drug Administration
Federal regulator
Granted accelerated approval and set postmarketing requirements

The federal agency that reviewed the biologics license application for Voceryq.
FDA Center for Biologics Evaluation and Research
FDA Center for Biologics Evaluation and Research
Federal regulatory agency division
Reviewed the Voceryq biologics license application

The FDA center responsible for regulating biologic products such as vaccines and gene therapies.

Timeline

October 2026 August 2032

8 events Latest: October 30th, 2026 · 1 week ago
Tap a bar to jump to that date

  1. Final study report due to FDA

    Upcoming Scheduled

    The report is the basis for deciding whether the approval is confirmed.

  2. Confirmatory study completion target

    Upcoming Scheduled

    The study must track surgical interventions for at least three years.

  3. Final confirmatory protocol due

    Upcoming Scheduled

    The FDA expects to align on the final study design by this date.

  4. Draft confirmatory protocol due to FDA

    Upcoming Scheduled

    INOVIO must submit its proposed design for the postmarketing study.

  5. FDA grants accelerated approval to Voceryq

    Latest Regulatory

    The approval covers adults with RRP and is based on reduced frequency of surgical papilloma excisions.

  6. FDA sets confirmatory trial deadlines

    Regulatory

    Draft protocol due December 30, 2026; final report due August 30, 2032.

  7. Inovio shares more than triple after hours

    Market

    The stock reached $2.17 after the approval was announced.

  8. FDA attaches device testing commitments to approval

    Regulatory

    In the approval letter, the FDA required Inovio to reanalyze human-factors testing of the Cellectra 5PSP delivery device, separating close calls from use difficulties, and to verify the device's sharps-injury prevention feature.

Scenarios

1

Confirmatory data hold up and FDA converts Voceryq to full approval

Possible Resolves by End of 2032

Discussed by: FDA approval letter; INOVIO

If the postmarketing study reproduces the reduction in surgeries across at least 50 adults and children over three years, the FDA can drop the accelerated-approval conditions. Conversion would stabilize reimbursement and remove the withdrawal risk that hangs over the label.

2

Confirmatory trial misses its endpoint and FDA moves to withdraw approval

Possible Resolves by Q2 2033

Discussed by: FDA approval letter, which states approval may be withdrawn if the study fails or lacks due diligence

The approval rests on 7 complete responses in 26 patients, a small single-arm result. If the larger study shows no durable reduction in surgery, the FDA has explicit authority to withdraw the indication, as it has for other accelerated approvals.

3

Pediatric patients gain access through a label expansion

Possible Resolves by End of 2032

Discussed by: FDA approval letter, which requires the confirmatory study to enroll pediatric patients

RRP also affects children, and the required study must include them. If the data support it, INOVIO could seek to extend the indication beyond adults, widening the market and the patient pool.

4

INOVIO sells or partners the Voceryq franchise before the confirmatory readout

Possible Resolves by End of 2028

Discussed by: Biotech analysts covering INOVIO

Commercializing a first product requires manufacturing, a delivery device, and payer negotiations. A company with no prior launch experience may choose to license rights or sell the asset rather than fund the launch and the confirmatory trial alone.

5

Device usability findings hold up the commercial launch

Possible Resolves by Q2 2027

Discussed by: FDA approval letter postmarketing commitments; Drug Discovery Trends

Voceryq is injected with Inovio's Cellectra 5PSP electroporation device, which the FDA approved alongside the drug. The agency ordered a reanalysis of human-factors testing and new validation of the device's sharps-injury protection. If that work finds a safety or usability problem, the device could need redesign, which would slow shipments that Inovio expects to begin about 60 days after approval.

Historical Context

3 moments from history that rhyme with this story — and how they unfolded.

November 2011

FDA withdraws Avastin's breast cancer indication (2011)

Avastin won accelerated approval for metastatic breast cancer in 2008. Follow-up trials showed no improvement in overall survival, and the FDA moved to withdraw the indication over the manufacturer's objection.

Then

Genentech appealed; the FDA commissioner upheld the withdrawal after a hearing.

Now

The drug stayed on the market for other cancers, and the case became the standard example of how accelerated approval can be reversed.

Why this matters now

Voceryq's approval carries the same conditional structure. If the confirmatory study fails, the FDA can pull the indication.

April 2010

Provenge, the first therapeutic cancer vaccine (2010)

The FDA approved sipuleucel-T, a personalized cellular immunotherapy for prostate cancer, as the first therapeutic cancer vaccine. Manufacturing required collecting and processing each patient's own cells.

Then

Launch costs and complex logistics limited uptake despite the approval.

Now

Dendreon filed for bankruptcy in 2014, and the product was later sold.

Why this matters now

A first-in-class immunotherapy can still struggle on delivery and cost. Voceryq needs a proprietary electroporation device and a supply chain INOVIO has never run at commercial scale.

June 2006

HPV vaccine licensed in the U.S. (2006)

The FDA licensed Gardasil, the first vaccine against HPV types 6, 11, 16, and 18. Types 6 and 11 cause most recurrent respiratory papillomatosis.

Then

The vaccine was recommended for adolescents, and uptake built slowly.

Now

Vaccination reduces the incidence of the HPV types that cause RRP, but existing patients still need treatment.

Why this matters now

Voceryq treats the same HPV types the vaccine prevents. It addresses people already infected, a population vaccination cannot reach retroactively.

Sources

(12)
+6
U.S. Food and Drug Administration INOVIO Pharmaceuticals Voceryq HCP MarketWatch HCPLive WHBL Regulatory News Drug Discovery Trends Credence Research Nature Reviews Drug Discovery U.S. Food and Drug Administration U.S. Food and Drug Administration